Patients with immunocompromising conditions are at higher risk of vaccine-preventable infections. Further, those receiving immunosuppressive disease-modifying antirheumatic drugs (DMARDs) can have variable responses to vaccines depending on which vaccine and which DMARD they are receiving.
- Influenza vaccine should be given yearly to all patients on DMARDs
- with modification to either the timing of DMARD or vaccine administration for patients receiving methotrexate or rituximab
ASJC Scopus subject areas